Refine by
Applications
- Freeze-Dried Hemostatic for Patients
- Microbiome Therapeutics for Clinical Trials
- Flagship Coil for Major Depressive Disorder (MDD) Treatment
- Flagship Coil for Anxious Depression Treatment
- Flagship Coil for Obsessive-Compulsive Disorder (OCD) Treatment
- Flagship Coil for Smoking Addiction Treatment
- Flagship Coil for Bipolar Disorder Treatment
- Flagship Coil for Post Traumatic Stress Disorder Treatment Treatment
- Flagship Coil for Schizophrenia (Negative Symptoms) Treatment
- Flagship Coil for Alzheimer’s Disease Treatment
- Flagship Coil for Autism Disorder Treatment Technology
- The mat (t) isse bioprothesis: a bio-resorbable tec (tissue engineering chamber)
Clinical Stage Equipment & Supplies
70 equipment items found
by:CuraVac Europe S.A. based inRixensart, BELGIUM
CuraVac is a clinical-stage biotechnology company developing the medical and commercial potential of a revolutionary technique for the production of specific Therapeutic Vaccines (or Active Targeted Immunotherapies) for autoimmune ...
Manufactured by:Auro Vaccines LLC based inPearl River, NEW YORK (USA)
As part of its comprehensive Public Health and Biodefense vaccine franchise, under a license from the Henry M. Jackson Foundation, Auro Vaccines is developing a subunit vaccine (HeV-sG-V) composed of the envelope glycoprotein of Hendra virus for the prevention of Nipah virus (NiV) ...
Manufactured by:Salutaris Medical Devices, Inc. (SMD) based inTucson, ARIZONA (USA)
SalutarisMD [SMD] is a clinical stage medical device company. SMD's BetaCurve is a globally-patented, 510(k)-cleared device designed to treat various ophthalmic diseases with precision beta radiotherapy, including PCV. The BetaCurve™ curves around the back of the eye to precisely deliver therapeutic beta radiation to the diseased area using a fiber optic ...
by:NeoTherma Oncology based inWichita, KANSAS (USA)
NeoTherma Oncology is a clinical stage medical device company developing a proprietary Thermal Treatment (VectRx) system for deep solid tumors. Our technology is based on applying a safe, non-invasive, non-ionizing electromagnetic field to produce local-regional hyperthermic temperatures in tumor tissue, intended to increase the effectiveness of anticancer ...
Manufactured by:Auro Vaccines LLC based inPearl River, NEW YORK (USA)
Auro Vaccines has developed VesiculoVax™-vectored vaccines for pre- and post-exposure protection against the hemorrhagic disease caused by multiple species of filovirus (i.e. Zaire ebolavirus, Sudan ebolavirus and Marburg ...
Manufactured by:Auro Vaccines LLC based inPearl River, NEW YORK (USA)
Auro Vaccines is developing a GeneVax prime/VesiculoVax boost therapeutic HPV vaccine for use as an adjunct to surgery that targets the seven HPV types responsible for more than 92% of cervical and head and neck ...
Manufactured by:Elpiscience based inShanghai, CHINA
ES002’s dual ATP-adenosine mechanism is a potentially powerful TME regulator and transformative cancer immunotherapy. In preclinical studies ES002 demonstrated significant single agent anti-tumor activity as well as an excellent tolerability profile. ES002 has also shown superior enzymatic inhibition and binding ...
Manufactured by:Adrenomed AG based inBerlin, GERMANY
The Company’s lead product candidate is Adrecizumab (HAM8101; INN: enibarcimab), a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Adrecizumab is supported by the elegance of its mode of action, a monoclonal antibody that on binding to its target Adrenomedullin preserves its functionality as regulator of ...
Manufactured by:Femasys Inc. based inSuwanee, GEORGIA (US) (USA)
FemBloc features our proprietary delivery platform, which places balloon technology close to the opening of both fallopian tubes. This in-office approach is designed to eliminate the risks of incisions, anesthesia, and hormones. As a nonsurgical procedure that is implant free, FemBloc delivers a biopolymer that is expected to expel within 3 months. Confirmation of procedure success can be ...
Manufactured by:Synaffix BV based inOss, NETHERLANDS
GlycoConnect™ replaces the existing antibody glycan with a therapeutic payload. Synaffix has established a simple, yet powerful, clinical-stage platform technology enabling best-in-class ADCs, bispecific antibodies and the targeted delivery of various other therapeutic payloads, all without modifying the antibody ...
by:STALICLA based inGeneve, SWITZERLAND
DDU validates ASD phenotype groups and drug candidates through observational studies and investigational trials. DDU combines expertise in operations, medicine, drug and clinical development, to bring STALICLA’s clinical-stage treatment options closer to ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Yso1 is a clinical stage development program aiming at harnessing the potential of Christensenella minuta as a groundbreaking biotherapy to treating obesity and metabolic disorders. The goal of our disruptive approach is to return to obese patients christensenella, which have the unique ability to repair the unbalanced microbiome, thereby restoring impaired key ...
Manufactured by:Alphageneron based inCambridge, MASSACHUSETTS (USA)
Our lead clinical stage natural killer (NK) cell therapy, is an autologous platform technology that activates NK cells to kill cancers expressing a unique membrane form of Heat Shock Protein 70 ...
Manufactured by:Navigo Proteins GmbH based inHalle, GERMANY
Navigo Proteins’ Precision Capturing® technology dramatically simplifies non-Fc biologics downstream processing from pre-clinical stage to commercial manufacturing. This is achieved by substituting several chromatography steps by one single custom affinity chromatography capture step based on Navigo’s proprietary artificial Protein A affinity ...
Manufactured by:AMS Biotechnology (Europe) Ltd. based inAbingdon, UNITED KINGDOM
Breast cancer with adjacent normal breast tissue array (2012 WHO classification), including pathology grade, TNM and clinical stage (AJCC 7th edition), 12 cases/24 cores, repalcing BR245. Breast carcinoma with adjacent normal breast tissue microarray, containing 10 cases of invasive carcinoma of no special type, 2 adjacent normal breast tissue, duplicate cores ...
Manufactured by:AVEO Pharmaceuticals, Inc. based inBoston, MASSACHUSETTS (USA)
AV-203 (CAN017) is a clinical-stage ErbB3 (HER3) inhibitory antibody candidate designed to inhibit both ligand-dependent and ligand-independent ErbB3 signaling. ErbB3 is a receptor that is typically expressed in many human cancers, and AV-203 has demonstrated preclinical activity in a number of different tumor models including breast, head and neck, lung, ovarian ...
by:LIXTE Biotechnology Holdings, Inc. based inPasadena, CALIFORNIA (USA)
The series has the potential to be the most effective in its class and may be useful for the treatment of chronic hereditary diseases, such as Gaucher’s disease, in addition to cancer and neurodegenerative diseases. LB-200 has not yet advanced to the clinical stage and would require additional capital to fund further development. Accordingly, because of our ...
Manufactured by:Frontier Biotechnologies Inc. based inNanjing, CHINA
Licensed with exclusive rights for greater China from AFFiRiS AG, a clinical-stage biotechnology company in Austria, FB6001 is an investigational therapeutic peptide vaccine targeting PCSK9 to treat hypercholesterolemia. PCSK9 is a clinically validated target and FB6001 is a potential first-in-class immunotherapy for hypercholesteremia. FB6001 is ...
Manufactured by:Cellphire Therapeutics, Inc. based inRockville, MARYLAND (USA)
Cellphire Therapeutics is committed to transforming hemostasis management with innovative products that fill critical gaps in the treatment of bleeding patients. Our lead clinical-stage candidate, Thrombosomes, is an activated platelet-based hemostatic. The product is currently in a Phase 2 clinical trial in bleeding thrombocytopenic patients. ...
Manufactured by:Vivesto AB based inSolna, SWEDEN
Cantrixil is a product candidate in clinical stage being developed for the treatment of ovarian cancer. Cantrixil consists of the active molecule, a potent and selective third generation benzopyran SMETI inhibitor named TRXE-002-01, encapsulated in a cyclodextrin. It is believed to target a wide spectrum of cancer cells, including chemotherapy-resistant ...